Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated reports developments for a global medical technology business that supplies hospitals and healthcare providers with devices used in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Its established brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Recurring Teleflex news covers quarterly financial results, outlook updates, revenue trends by global product category, portfolio realignment and integration of acquired vascular intervention assets. Company updates also include governance and leadership changes, board committee matters, capital allocation actions, shareholder communications and operational initiatives such as integrated demand and supply planning.
Teleflex (NYSE: TFX) reported four‑year BIOMAG™‑I data for the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G), covering 116 patients at European centers.
No cardiac death, target‑vessel myocardial infarction, or definite/probable scaffold thrombosis were seen through four years, and target lesion failure was 3.5%, supporting favorable long‑term safety and sustained performance.
Teleflex (NYSE: TFX) priced a private offering of $500 million aggregate principal amount of 5.875% senior notes due 2032 at 100.000%. Closing is expected on June 15, 2026, subject to customary conditions. Net proceeds plus cash will redeem existing 4.625% notes due 2027.
The new notes will be guaranteed by certain wholly owned domestic subsidiaries and are offered only to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S.
Teleflex (NYSE: TFX) announced the commencement of a private offering of $500 million in senior notes due 2032, with interest rate and terms set at pricing. The notes will be guaranteed by certain domestic subsidiaries, and net proceeds plus cash are intended to redeem all outstanding 4.625% senior notes due 2027.
Teleflex (NYSE: TFX) reported new clinical data from its Interventional Urology business at AUA 2026 and ESTRO 2026. Findings include favorable early patient experience with the UroLift System versus Rezūm for BPH, and three-year reductions in gastrointestinal toxicity with the Barrigel rectal spacer for prostate cancer.
The Interventional Urology unit continues to build clinical evidence as it prepares for a planned divestiture in the second half of 2026.
Teleflex (NYSE: TFX) announced that its Board of Directors declared a quarterly cash dividend of $0.34 per share on common stock. The dividend will be paid on June 30, 2026 to shareholders of record as of May 25, 2026.
Teleflex (NYSE: TFX) reported Q1 2026 continuing operations revenue of $548.3M, up 32.3% year-over-year and 5.1% on a pro forma adjusted constant currency basis. GAAP diluted EPS was $(0.11); adjusted diluted EPS was $1.39. Company reaffirmed full-year 2026 guidance: GAAP revenue growth 14.4%–15.4%, adjusted EPS $6.25–$6.55, and expects Strategic Divestitures to close in H2 2026.
Key balance-sheet notes: cash $329.6M, inventories $380.9M, net AR $365.5M; stranded costs estimated at $90M; intends ~$1B buyback and ~$800M debt paydown.
Teleflex (NYSE: TFX) appointed Jason Weidman as President and CEO, effective June 8, 2026. He will join the board upon assuming the role and succeeds Stuart Randle, who remains a director. The company said Weidman brings 25+ years in medical technology and global operating-unit experience.
Teleflex noted pending divestitures and an intended capital plan including a $1.0 billion share buyback and $800 million debt paydown to reposition the company toward interventional, critical care, and high-acuity hospital markets.
Teleflex (NYSE:TFX) will host a conference call to discuss its first quarter 2026 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 7, 2026.
Investors can pre-register to receive dial-in details, listen via a live audio webcast at teleflex.com, and access an audio replay beginning at 11:00 a.m. Eastern Time on May 7, 2026 (conference ID 69028).
Teleflex (NYSE:TFX) announced Board and governance changes on April 9, 2026, including the nomination of Michael J. Tokich as an independent director and the appointment of Andrew A. Krakauer as Chairman effective after the 2026 Annual Meeting.
The Board will form a Growth and Operating Committee to support transformation efforts, and the company plans to commence opportunistic share repurchases under its existing $1 billion authorization beginning in Q2 2026, subject to market conditions and cash flow needs.
Irenic Capital Management, a 2% shareholder in Teleflex (NYSE: TFX), urged the Teleflex board to form a Strategic Review sub-committee with new independent directors, a shareholder representative and exclusion of Dr. Klasko to oversee inbound and outbound strategic processes and report back to shareholders.
Irenic said it disagrees with the board's description of their prior conversation and said it looks forward to working with the board to maximize shareholder value.